Anorectic Drugs Research Articles

Rational use of short-term anorectic drugs for one-year effective treatment of obesity: An analysis of four studies.

Obesity is a complex disease for which pharmacotherapy is often used. Anti-obesity drugs (AODs) are characterized by inducing a variable inter-subject body weight reduction (BWR), the attainment of a plateau after their maximal effect is achieved, and weight regain after drug discontinuation, which complicate individualized treatment of obesity. This exploratory analysis aimed to compare the first-month body weight reduction in kg (1mo-BWRkg) and tolerance development (moT) of four known interventions with low (placebo), intermediate (phentermine or mazindol monotherapy), and high (5 active ingredients fixed-dose combination) efficacy, as predictors of their 6-month body weight reduction efficacy in percent (6mo-BWR%). In addition, a detailed analysis of the 6-to-12-month BWR follow-up in subjects under orlistat or diet and exercise regimens was performed. The analysis included 662 adult subjects with obesity. After the construction of average efficacy and weight rebound curves, subjects were grouped into various 1mo-BWRkg, moT, and 6mo-BWR% intervals, or 6-month body weight rebound parameters for further evaluation. The 6mo-BWR% efficacy level of interventions was confirmed, although a general high intersubject variation was observed. 1mo-BWRkg + moT was found as an acceptable predictor of 6mo-BWR%. Between 50 and 80% of the 6-to-12-month follow-up completers maintained at least 5% BWR%. Short-term AODs are useful adjuvants for the 1-year rational treatment of obesity. 1mo-BWRkg + moT is an acceptable parameter to predict the 6mo-BWR% efficacy of these interventions.

Cardiac valvular surgery and history of anorectic drug intake: A retrospective study of a large population of benfluorex-exposed patients

Anorectic drugs are overlooked as a cause of valvular heart disease (VHD). To describe the characteristics of a large population of patients with severe VHD who underwent cardiac surgery and had a history of benfluorex intake. Retrospective observational and cross-sectional study of patients from a large French database (Office National d'Indemnisation des Accidents Médicaux). Clinical, echocardiographic, surgical and pathology findings were comprehensively collected from medical files. From a chart review of 9584 subjects, 1031 patients with VHD underwent cardiac surgery; 453 surgical patients were excluded because of VHD obviously unrelated to benfluorex exposure, six because of missing data and eight declined to participate. The final study population comprised 564 patients who had surgery between 1987 and 2019. Median age was 58 (interquartile range 50-65) years; 85% were female. Median duration of preoperative benfluorex exposure was 5.8 (3.3-10) years. Most patients had aortic and mitral valve disease. Pure or predominant aortic and/or mitral regurgitation were found in 84% of patients (n=471), and aortic or mitral stenosis (pure or combined with regurgitation) in 12% (n=67) and 15% (n=84), respectively. Overall, 403 aortic, 402 mitral and 64 tricuspid valve surgical procedures were collected. Aortic and mitral valves were found to be thickened, rigid and/or restrictive in most cases; restrictive tricuspid valve disease was seldom documented. Pathology was available in half of the population (276 patients); valvular fibrosis suggestive of drug-induced VHD was found in 222 patients, including 146 with expert examination. Mixed VHD aetiologies were discussed in 107 patients, including 54 with available pathology. Drug-induced VHD features are miscellaneous, including well-known restrictive valvular regurgitation, but also stenosis or combined regurgitation and stenosis. Besides a history of drug taking, thorough echocardiography and comprehensive surgical reports, pathology is key in the diagnostic procedure.

Ion channels as convergence points in the pathology of pulmonary arterial hypertension.

Pulmonary arterial hypertension (PAH) is a fatal disease of the cardiopulmonary system that lacks curative treatments. The main pathological event in PAH is elevated vascular resistance in the pulmonary circulation, caused by abnormal vasoconstriction and vascular remodelling. Ion channels are key determinants of vascular smooth muscle tone and homeostasis, and four PAH channelopathies (KCNK3, ABCC8, KCNA5, TRPC6) have been identified so far. However, the contribution of ion channels in other forms of PAH, which account for the majority of PAH patients, has been less well characterised. Here we reason that a variety of triggers of PAH (e.g. BMPR2 mutations, hypoxia, anorectic drugs) that impact channel function may contribute to the onset of the disease. We review the molecular mechanisms by which these ‘extrinsic’ factors converge on ion channels and provoke their dysregulation to promote the development of PAH. Ion channels of the pulmonary vasculature are therefore promising therapeutic targets because of the modulation they provide to both vasomotor tone and proliferation of arterial smooth muscle cells.

Fenfluramine as antiseizure medication for epilepsy.

Fenfluramine hydrochloride has classically been described as acting pharmacologically through a serotonergic mechanism. Therefore, it was initially used as an anorectic drug, given that impaired serotonin homeostasis may be associated with increased food intake. Although positive results were documented, cardiovascular concerns resulted in its temporary withdrawal. Nevertheless, a novel role in patients with epilepsy was later suggested by isolated clinical observations. The wide application of genetic testing allowed the classification (predominantly as Dravet syndrome) of patients in whom benefit was seen, while with the development of zebrafish models, its antiepileptic properties were confirmed at a molecular level. Data from randomized clinical trials have shown a beneficial effect of fenfluramine, as an adjunct therapy, on seizure control for children with Dravet syndrome, though there is still uncertainty about the impact on neurodevelopment in these patients. No signs of heart valve disease have been documented to date. Long-term and appropriately designed clinical studies will verify whether fenfluramine is a therapeutic agent of high importance, living up to the promise shown so far. What this paper adds Fenfluramine is a very promising repurposed therapy specifically for seizures in Dravet syndrome. The long-term effect of fenfluramine on neurodevelopmental prognosis requires further investigation.

Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling.

Several clinical reports indicate that the use of amphetaminic anorectic drugs or ergot derivatives could cause valvular heart disease (VHD). We sought to investigate whether valvular lesions develop in response to long-term oral administration of these drugs and to identify drug-targeted biological processes that may lead to VHD. Treatment of New Zealand White rabbits with pergolide, dexfenfluramine, or high-dose serotonin for 16 weeks induced valvular alterations characterized by extracellular matrix remodeling. Transcriptome profiling of tricuspid valves using RNA sequencing revealed distinct patterns of differentially expressed genes (DEGs) that clustered according to the different treatments. Genes that were affected by the three treatments were functionally enriched for reduced cell metabolism processes. The two drugs yielded more changes in gene expression than serotonin and shared most of the DEGs. These DEGs were mostly enriched for decreased biosynthetic processes, increased cell-matrix interaction, and cell response to growth factors, including TGF-β, which was associated with p38 MAPK activation. Treatment with pergolide specifically affected genes involved in homeostasis, which was corroborated by the activation of the master regulator of cell energy homeostasis, AMPK-α, as well as decreased levels of metabolism-related miR-107. Thus, both pergolide and dexfenfluramine may cause VHD through valve metabolic reprogramming and matrix remodeling.

The homeostatic dynamics of feeding behaviour identify novel mechanisms of anorectic agents.

Better understanding of feeding behaviour will be vital in reducing obesity and metabolic syndrome, but we lack a standard model that captures the complexity of feeding behaviour. We construct an accurate stochastic model of rodent feeding at the bout level in order to perform quantitative behavioural analysis. Analysing the different effects on feeding behaviour of peptide YY3-36 (PYY3-36), lithium chloride, glucagon-like peptide 1 (GLP-1), and leptin shows the precise behavioural changes caused by each anorectic agent. Our analysis demonstrates that the changes in feeding behaviour evoked by the anorectic agents investigated do not mimic the behaviour of well-fed animals and that the intermeal interval is influenced by fullness. We show how robust homeostatic control of feeding thwarts attempts to reduce food intake and how this might be overcome. In silico experiments suggest that introducing a minimum intermeal interval or modulating upper gut emptying can be as effective as anorectic drug administration.

USE OF SIBUTRAMIN IN PHARMACEUTICAL DRUGS AND ANOREXIC DIETARY SUPPLEMENTS (REVIEW)

Background. The most effective anorexic drugs on the pharmaceutical market are sibutramine. According to the standard scheme, sibutramine is similar to amphetamine. The active metabolites of sibutramine, formed in the process of its metabolism, have high pharmacological activity compared with the original substances, so the drug may be toxic to the body. Sibutramine is used in the complex treatment of obesity, when adjusting excess body weight in type II diabetes, and also used in polycystic ovary syndrome. The drug has many serious undesirable side effects, such as an increase in systolic and / or diastolic pressure and heart rate; headaches, insomnia, disorders of the gastrointestinal tract and can cause death. In many countries of the world a wide range of serious side effects has been banned. Text. A description of the drug sibutramine, its status on the pharmaceutical market of the Russian Federation and other countries of the world, an overview of possible methods for determining sibutramine in food supplements. Conclusion. Recently, information about the undeclared addition of sibutramine to the anorexigenic dietary supplement (dietary supplement) to increase their effectiveness has increasingly appeared. Therefore, it is necessary to develop methods for determining sibutramine in anorexic dietary supplements. In this regard, an analysis of the methods used for the quantitative determination of sibutramine. As a rule, spectral methods are used to determine the authenticity of a sibutramine substance. The most common and effective method for determining authenticity and quantitative analysis of sibutramine is the HPLC (high performance liquid chromatography) method using mass spectrometric and diode array detectors (DAD). At the moment, a method for determining sibutramine in the composition of multicomponent drugs and dietary supplements to food of anorexigenic action is being developed, which will contribute to the development of pharmacy.

Role of hypothalamic leptin-LepRb signaling in NPY-CART-mediated appetite suppression in amphetamine-treated rats

Leptin is an adipose tissue hormone which plays an important role in regulating energy homeostasis. Amphetamine (AMPH) is a drug of appetite suppressant, which exerts its effect by decreasing the expression of hypothalamic neuropeptide Y (NPY) and increasing that of cocaine- and amphetamine-regulated transcript (CART). This study investigated whether leptin, the leptin receptor (LepRb) and the signal transducer and activator of transcription-3 (STAT3) were involved in NPY/CART-mediated appetite suppression in AMPH-treated rats. Rats were given AMPH daily for four days, and changes in the levels of blood leptin and hypothalamic NPY, CART, LepRb, Janus kinases 2 (JAK2), and STAT3 were assessed and compared. During the AMPH treatment, blood leptin levels and hypothalamic NPY expression decreased, with the largest reduction observed on Day 2. By contrast, the expression of hypothalamic CART, LepRb, JAK2, and STAT3 increased, with the maximum response on Day 2. Furthermore, the binding activity of pSTAT3/DNA increased and was expressed in similar pattern to that of CART, LepRb, and JAK2. An intracerebroventricular infusion of NPY antisense 60min prior to AMPH treatment increased the levels of leptin, as well as the expression in LepRb, JAK2, and CART, whereas an infusion of STAT3 antisense decreased these levels and the expression of these parameters. The results suggest that blood leptin and hypothalamic LepRb-JAK2-STAT3 signaling involved in NPY-CART-regulated appetite suppression in AMPH-treated rats. The findings may aid understanding the role of leptin-LepRb during the treatment of anorectic drugs.

Impact of anorectic drugs fenfluramine, dexfenfluramine, lorcaserin, and rimonabant on obesity

Anorectic drugs are used to suppress appetite and increase satiety, thereby encouraging weight loss. Among the anorectic drugs that have been most commonly used are fenfluramine, dexfenfluramine, lorcaserin, and rimonabant, which promote weight loss in different ways and to different degrees. By reviewing recent literature, this paper comparatively assesses the benefits and risks of these anorectic drugs. Fenfluramine and dexfenfluramine, while highly effective in promoting weight loss, were associated with the highest risk of potentially fatal cardiac valve damage. Lorcaserin has proven to be significantly safer than fenfluramine and dexfenfluramine, but its impacts on weight loss were generally modest and it was less sucessful in promoting long-term weight loss. Rimonabant resulted in a more significant decrease in weight than did lorcaserin, but was associated with unpredictable psychological side effects. This review identifies lorcaserin as the safest of the anorectic drugs discussed, even if it is not the most effective in promoting and sustaining weight loss. While anorectic drugs may help to treat obesity, they are not without potentially harmful side effects and are best used in conjunction with dietary and lifestyle modifications. Future research should seek to improve the specificity of anorectic drugs and thereby reduce potential side effects.

Mazindol: a risk factor for pulmonary arterial hypertension?

Mazindol is an imidazo-isoindole derivative, a tricyclic compound and a non-amphetamine central nervous system stimulant that blocks dopamine and norepinephrine reuptake. Mazindol was withdrawn from the US and European markets in 1999 for reasons unrelated to its efficacy or safety around a time when other anorexic drugs were found to be associated with the development of pulmonary arterial hypertension (PAH). Despite the use of mazindol for decades, reports of PAH due to mazindol intake have been extremely rare. Recent interest on mazindol has emerged for the treatment of narcolepsy and attention-deficit/hyperactivity disorder. Therefore, an updated understanding of the potential benefits and risks of mazindol in these patient populations is warranted.

Measuring the Consumption of Individual Solid and Liquid Bites Using a Table-Embedded Scale During Unrestricted Eating.

The universal eating monitor (UEM) is a table-embedded scale used to measure grams consumed over time while a person eats. It has been used in laboratory settings to test the effects of anorectic drugs and behavior manipulations such as slowing eating, and to study relationships between demographics and body weight. However, its use requires restricted conditions on the foods consumed and behaviors allowed during eating in order to simplify analysis of the scale data. Individual bites can only be measured when the only interaction with the scale is to carefully remove a single bite of food, consume it fully, and wait a minimum amount of time before the next bite. Other interactions are prohibited such as stirring and manipulating foods, retrieving or placing napkins or utensils on the scale, and in general anything that would change the scale weight that was not related to the consumption of an individual bite. This paper describes a new algorithm that can detect and measure the weight or individual bites consumed during unrestricted eating. The algorithm works by identifying time periods when the scale weight is stable, and then, analyzing the surrounding weight changes. The series of preceding and succeeding weight changes is compared against patterns for single food bites, food mass bites, and drink bites to determine if a scale interaction is due to a bite or some other activity. The method was tested on 271 subjects, each eating a single meal in a cafeteria setting. A total of 24101 bites were manually annotated in synchronized videos to establish ground truth as to the true, false, and missed detections of bites. Our algorithm correctly detected and weighed approximately 39% of bites with approximately one false positive (FP) per ten actual bites. The improvement compared to the UEM is approximately three times the number of true detections and a 90% reduction in the number of FPs. Finally, an analysis of bites that could not be weighed compared to those that could be weighed revealed no statistically significant difference in average weight. These results suggest that our algorithm could be used to conduct studies using a table scale outside of laboratory or clinical settings and with unrestricted eating behaviors.

Genotoxicity of antiobesity drug orlistat and effect of caffeine intervention: an in vitro study

Context: Obesity is a major global health problem associated with various adverse effects. Pharmacological interventions are often necessary for the management of obesity. Orlistat is an FDA-approved antiobesity drug which is a potent inhibitor of intestinal lipases. Objective: In the current study, orlistat was evaluated for its genotoxic potential in human lymphocyte cells in vitro and was compared with that of another antiobesity drug sibutramine, presently withdrawn from market due its undesirable health effects. Caffeine intake may be an additional burden in people using anorectic drugs, therefore, further work is needed to be carried out to evaluate the possible effects of caffeine on orlistat-induced DNA damage. Materials and methods: Human lymphocytes were exposed to orlistat (250, 500 and 1000 μg/ml), sibutramine (250, 500 and 1000 μg/ml) and caffeine (25, 50, 75, 100, 125 and 150 μg/ml) to assess their genotoxicity by comet assay in vitro. In addition, lymphocytes were co-incubated with caffeine (50, 75 and 100 μg/ml) and a single concentration of orlistat (250 μg/ml). Results: Orlistat and sibutramine were genotoxic at all concentrations tested, sibutramine being more genotoxic. Caffeine was found to be genotoxic at concentrations 125 μg/ml and above. Co-treatment of orlistat with non-genotoxic concentrations (50, 75 and 100 μg/ml) of caffeine lead to a decrease in DNA damage. Discussion and conclusion: Orlistat can induce DNA damage in human lymphocytes in vitro and caffeine was found to reduce orlistat-induced genotoxicity.

Test purchase, synthesis and characterization of 3‐fluorophenmetrazine (3‐FPM) and differentiation from its ortho‐ and para‐substituted isomers

The knowledge captured in patent and scientific research literature stimulates new ideas and fosters new drug development efforts. Manufacturers and entrepreneurs dedicated to the sale of 'research chemicals' and/or new psychoactive substances (NPS) also make use of access to information to identify, prepare, and launch a range of new substances. One of the most recent compounds to appear on the NPS market is the phenmetrazine analog 3-fluorophenmetrazine (3-FPM) which represents one of many phenylmorpholines designed to explore treatment options in areas such as obesity and drug dependence. The anorectic drug analogs phenmetrazine and phendimetrazine, used as prescription medicines before they were withdrawn, feature amphetamine-like properties associated with monoamine release. Available data on 3-FPM suggest that the effects might show mechanistic overlaps. This study describes the synthesis and extensive analytical characterization of 3-FPM and its differentiation from synthesized ortho- and para- substituted isomers, 2-FPM and 4-FPM, respectively. This study was triggered by the purchase of five powdered samples advertised as 3-FPM by five different Internet vendors based in the United Kingdom. The analytical data obtained for the vendor samples were consistent with the synthesized 3-FPM standard and differentiation between all three isomers was possible. The presence of positional isomers and the absence of suitable reference material can cause difficulties in the day-to-day operation of forensic work and given the rate at which many of the newly emerging NPS appear on the market, a comprehensive approach is needed when attempting to decipher the identity of NPS arriving onto the drug market. Copyright © 2016 John Wiley & Sons, Ltd.

QUALIDADE DE CÁPSULAS DE SIBUTRAMINA 10 MG MANIPULADAS EM TRÊS FARMÁCIAS DE BELO HORIZONTE – MG

<p>A sibutramina é um anorexígeno indicada como fármaco de primeira escolha para o tratamento da obesidade. Devido a inexistência de monografia farmacopeica para análise e controle de qualidade deste fármaco e que a sibutramina apresenta classificação biofarmacêutica I, os autores desse trabalho propuseram ensaios físico-químicos de qualidade e avaliação da influência dos excipientes na dissolução de cápsulas de sibutramina 10 mg manipuladas em três farmácias de Belo Horizonte – MG. Foram aplicados os métodos gerais descritos na Farmacopeia Brasileira 5 ed e foi feita co-validação de método espectrofotométrico UV. Os resultados indicam que das três amostras somente uma cumpriu com todas as especificações de qualidade.</p>

Three unusual cases of sudden cardiac death related to anorectic drugs

Three unusual cases of sudden cardiac death related to anorectic drugs

Development of an analytical method for simultaneous detection of psychotropic phenylalkylamines in hair by LC-MS/MS with a multi-mode reversed-phase column using pH gradient elution

Phenylalkylamine derivatives, such as methamphetamine (MA), 3,4-methylenedioxymethamphetamine (MDMA), phentermine, fenfluramine, phendimetrazine, amfepramone, and ketamine, are widely abused recreational or anorectic drugs in Korea, and their abuse has become a serious social problem. Hair is a useful specimen to prove chronic use and liquid chromatography-tandem mass spectrometry (LC-MS/MS) has recently become a more popular tool for hair analysis due to sensitivity and simplicity in sample preparation. In order to overcome limitations of standard reversed-phase column to separate low molecular weight amines, we adopted a multi-mode reversed-phase column, Scherzo SS-C18, which was composed of strong ionic ligands and C18 ligands, and used pH gradient elution to separate seven psychotropic phenylalkylamines and their metabolites. The essential validation parameters including selectivity, LOD, LLOQ, linearity, intra- and inter-assay precision and accuracy, recovery, and the matrix effect were satisfactory. The LODs ranged from 0.1ng/5mg hair (diethylnorephedrine, fenfluramine, ketamine, and MA) to 0.5ng/5mg hair (amfepramone, MDA, phendimetrazine, and phentermine). The LLOQs were 1ng/5mg hair for all analytes. The developed method was successfully applied to determination of phenylalkylamines in authentic hair samples analyzed previously by a routine gas chromatography/mass spectrometry (GC–MS) method. A good correlation was observed between the two methods, with a slope near one.

PROFILE OF PATIENTS WHO SEEK THE BARIATRIC SURGERY.

Background : Nowadays obesity is a chronic disease considered one of the greatest problems in public healthy. Showing to be effective in a short and long term, the bariatric surgery has emerged as an optional treatment for morbid obesity. Aim: Identify the profile of patients seeking bariatric surgery. Methods: Were interviewed 100 patients in preoperative nutritional monitoring of bariatric surgery. The study was conducted by applying a questionnaire prepared according to the research objectives. Results: From the individuals that were seeking bariatric surgery, 78% were female, 62% were married and 69% reported physical activity. The average age of those surveyed was 37±10.83 years and mean body mass index (BMI) was 43.51± 6.25 kg/m². The comorbidity more prevalent in this group was high blood pressure (51%). In previous treatments for weight reduction, 92% have already done hypocaloric diet followed by anorectic drug (83%). The success of these treatments was reported by 92% of patients; however, the weight lost was recovered in less than one year of 75%. Patients with diabetes mellitus and dyslipidemia had higher BMI values. The patients with comorbidities showed lower levels of BMI. Conclusion: The profile of patients who sought surgical treatment for their obesity were predominantly women with a family background of obesity and obesity-related comorbidities, especially hypertension and diabetes mellitus.

Differential regulation of metabolic parameters by energy deficit and hunger

AimsHypocaloric diet decreases both energy expenditure (EE) and respiratory exchange rate (RER), affecting the efficacy of dieting inversely. Energy deficit and hunger may be modulated separately both in human and animal studies by drug treatment or food restriction. Thus it is important to separate the effects of energy deficit and hunger on EE and RER. MethodsThree parallel and analogous experiments were performed using three pharmacologically distinct anorectic drugs: rimonabant, sibutramine and tramadol. Metabolic parameters of vehicle- and drug-treated and pair-fed diet-induced obese mice from the three experiments underwent common statistical analysis to identify effects independent of the mechanisms of action. Diet-induced obesity (DIO) test of tramadol was also performed to examine its anti-obesity efficacy. ResultsRER was decreased similarly by drug treatments and paired feeding throughout the experiment irrespective of the cause of reduced food intake. Contrarily, during the passive phase, EE was decreased more by paired feeding than by both vehicle and drug treatment irrespective of the drug used. In the active phase, EE was influenced by the pharmacological mechanisms of action. Tramadol decreased body weight in the DIO test. ConclusionsOur results suggest that RER is mainly affected by the actual state of energy balance; conversely, EE is rather influenced by hunger. Therefore, pharmacological medications that decrease hunger may enhance the efficacy of a hypocaloric diet by maintaining metabolic rate. Furthermore, our results yield the proposal that effects of anorectic drugs on EE and RER should be determined compared to vehicle and pair-fed groups, respectively, in animal models.

Fully-automated, high-throughput micro-computed tomography analysis of body composition enables therapeutic efficacy monitoring in preclinical models.

The ability to non-invasively measure body composition in mouse models of obesity and obesity-related disorders is essential for elucidating mechanisms of metabolic regulation and monitoring the effects of novel treatments. These studies aimed to develop a fully automated, high-throughput micro-computed tomography (micro-CT)-based image analysis technique for longitudinal quantitation of adipose, non-adipose and lean tissue as well as bone and demonstrate utility for assessing the effects of two distinct treatments. An initial validation study was performed in diet-induced obesity (DIO) and control mice on a vivaCT 75 micro-CT system. Subsequently, four groups of DIO mice were imaged pre- and post-treatment with an experimental agonistic antibody specific for anti-fibroblast growth factor receptor 1 (anti-FGFR1, R1MAb1), control immunoglobulin G antibody, a known anorectic antiobesity drug (rimonabant, SR141716), or solvent control. The body composition analysis technique was then ported to a faster micro-CT system (CT120) to markedly increase throughput as well as to evaluate the use of micro-CT image intensity for hepatic lipid content in DIO and control mice. Ex vivo chemical analysis and colorimetric analysis of the liver triglycerides were performed as the standard metrics for correlation with body composition and hepatic lipid status, respectively. Micro-CT-based body composition measures correlate with ex vivo chemical analysis metrics and enable distinction between DIO and control mice. R1MAb1 and rimonabant have differing effects on body composition as assessed by micro-CT. High-throughput body composition imaging is possible using a modified CT120 system. Micro-CT also provides a non-invasive assessment of hepatic lipid content. This work describes, validates and demonstrates utility of a fully automated image analysis technique to quantify in vivo micro-CT-derived measures of adipose, non-adipose and lean tissue, as well as bone. These body composition metrics highly correlate with standard ex vivo chemical analysis and enable longitudinal evaluation of body composition and therapeutic efficacy monitoring.

ANÁLISE DAS PRESCRIÇÕES DE SIBUTRAMINA DISPENSADAS EM DROGARIAS NO MUNICÍPIO DE CUIABÁ-MT, BRASIL

A obesidade é uma doença metabólica caracterizada pelo aumento de massa corporal e/ou por um excesso de tecido adiposo no organismo. Dentre as opções farmacológicas, a sibutramina, é o medicamento mais indicado para indivíduos com sobrepeso. O objetivo do trabalho foi analisar as prescrições de sibutramina dispensadas nas drogarias de Cuiabá, Mato Grosso, Brasil em relação à distribuição da faixa etária, sexo, especialidade médica, bem como obter quais os principais erros de prescrições deste medicamento. Foram analisadas no período de três meses 815 receitas de controle especial, B2, na Vigilância Sanitária do município de Cuiabá-MT, decorrentes de cinco drogarias de rede aleatórias nos meses de julho, agosto e setembro do ano de 2014. Das quais, 83,7%, corresponderam a usuários do sexo feminino e restante ao sexo masculino. Quanto à faixa etária, observou-se a predominância entre 31–35 anos e em 9,94% foi ocultada a idade do paciente. A prescrição de sibutramina foi prevalente por clínicos gerais, seguido de endocrinologistas, sendo que entre os itens obrigatórios a ser preenchidos no receituário B2 não houve erros no preenchimento. De acordo com avaliação dos receituários, constata-se que o uso de sibutramina é prescrito sem diagnóstico preciso do grau de obesidade, o que acarreta problemas de saúde pública, bem como o uso irracional deste medicamento anorexígeno pela população cuiabana.